Eugene F. Collins advise Apica Cardiovascular on its sale to Thoratec
4 July 2014
Eugene F. Collins acted for medical devices company Apica Cardiovascular on its sale to Thoratec Corporation (NASDAQ: THOR) for $75m.
Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies for failing hearts, acquired Galway based Apica for an upfront cash payment of $35 million and potential future clinical and sales milestones of up to $40 million. As part of the agreement, the Apica team based in Ireland and the US will transition to Thoratec.
For further information contact John Olden, Partner, Corporate, E firstname.lastname@example.org